<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: The outcomes after Gamma Knife surgery (GKS) were retrospectively analyzed in patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> from radioresistant primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to evaluate the efficacy of GKS and the prognostic factors for local <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> control and overall survival </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The authors reviewed the medical records of 152 patients with 616 tumors </plain></SENT>
<SENT sid="2" pm="."><plain>The group included 102 men and 50 women aged 35-85 years (mean age 64.4 years), who underwent GKS for metastatic <z:mp ids='MP_0009277'>brain tumors</z:mp> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> between April 1992 and September 2008 at Yokohama Rosai Hospital </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The mean prescription dose to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> margin was 18.5 Gy (range 8-30 Gy) </plain></SENT>
<SENT sid="4" pm="."><plain>The mean <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume at GKS was 2.0 cm(3) (range 0.004-10.0 cm(3)) </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> were located in the colon in 88 patients and the rectum in 64 </plain></SENT>
<SENT sid="6" pm="."><plain>The median interval between the diagnosis of <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> and the diagnosis of <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> was 27 months (range 0-180 months) </plain></SENT>
<SENT sid="7" pm="."><plain>The median neuroradiological follow-up period after GKS was 3 months (mean 6.4 months, range 1-93 months) </plain></SENT>
<SENT sid="8" pm="."><plain>The local <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> control rate, based on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging, was 91.2% </plain></SENT>
<SENT sid="9" pm="."><plain>The significant factors for unfavorable local <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> control, based on multivariate analysis, were larger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume (p = 0.001) and lower margin dose (p = 0.016) </plain></SENT>
<SENT sid="10" pm="."><plain>The median overall survival time was 6 months </plain></SENT>
<SENT sid="11" pm="."><plain>Lower Karnofsky Performance Scale (KPS) score (p = 0.026) and the presence of extracranial <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (p = 0.004) at first GKS were significantly correlated with poor overall survival period in multivariate analysis </plain></SENT>
<SENT sid="12" pm="."><plain>The cause of <z:hpo ids='HP_0011420'>death</z:hpo> was <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> in 112 patients and <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological disease</z:e> in 13 patients </plain></SENT>
<SENT sid="13" pm="."><plain>Leptomeningeal <z:e sem="disease" ids="C0205699" disease_type="Neoplastic Process" abbrv="">carcinomatosis</z:e> was significantly correlated with a shorter duration of neurological survival in multivariate analysis (p &lt; 0.0001) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Gamma Knife surgery is effective for suppression of local <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> from radioresistant colorectal primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Therefore, clinical and radiological screening of intracranial <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> for patients with lower KPS scores and/or the presence of extracranial <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> as well as follow-up examinations after GKS for <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> should be performed periodically in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, because the neurological prognosis is improved by initial and repeat GKS for newly diagnosed or <z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">recurrent tumors</z:e> leading to a prolonged high-quality survival period </plain></SENT>
</text></document>